Speaker
Description
Cancer is a devastating disease that affects the lives of almost everyone, and its effective treatment still remains an important unmet medical need. In order to discover new cancer drugs, we are applying fragment-based methods and structure-based design to identify and optimize small molecules that inhibit highly validated cancer targets. Although many of these targets are technically challenging and thought to be undruggable, fragment-based methods offer several advantages over more conventional approaches which suggest that it may be possible to achieve success. In this presentation, examples will be given of how this methodology can be used to discover small molecules that bind to highly validated but technically challenging cancer targets.